News

February 9, 2018February 14, 2018

PD-1 Inhibitors May Help Children with Certain Form of Aggressive Brain Cancer, Study Says

News

Immune checkpoint inhibitors targeting the PD-1 pathway could be a promising approach in treating certain children with an aggressive form of brain cancer known as supratentorial pediatric ependymoma, researchers suggest. Their ... Read more

February 8, 2018February 8, 2018

Opdivo-Yervoy Combo Delays Disease Progression in Certain Patients with Advanced NSCLC, Study Shows

News

Patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high mutation burden lived longer without the disease progressing when receiving Opdivo (nivolumab) plus Yervoy (ipilimumab), compared to chemotherapy, ... Read more

February 7, 2018February 7, 2018

Opdivo-Yervoy Combo Shows Promise for Treating Certain Colorectal Cancers

News

A combination of the immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) induces durable responses in patients with metastatic colorectal cancer with certain genetic features, a Phase 2 clinical trial shows. ... Read more

February 6, 2018February 6, 2018

BeiGene Begins Administering Esophagus Cancer Immuno-oncology Therapy in Phase 3 Trial

News

BeiGene has begun administering tislelizumab (BGB-A317) to esophagus cancer patients taking part in a Phase 3 clinical trial. Researchers will assess tislelizumab as a second-line treatment for advanced unresectable or metastatic esophageal squamous ... Read more

February 5, 2018February 5, 2018

New Test Accurately Detects Early-stage Solid Tumors Using Only Blood Samples

News

A blood test can detect solid tumors with a high degree of accuracy, according to new data presented by the ITUS Corporation, which developed the technology. The test uses artificial ... Read more

February 2, 2018

Agenus Launches Combo Study of Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumors

News

Agenus has launched a Phase 1/2 clinical trial to test a combination of its proprietary anti-CTLA-4 (AGEN1884) and anti-PD-1 (AGEN2034) antibodies in patients with advanced solid tumors. The open-label study (ACTRN12618000003279) will ... Read more

February 1, 2018

BioLineRx’s AGI-134 Induces Tumor Regression, Improves Survival in Melanoma Mice

News

Treating melanoma mouse models with an intratumoral injection of BioLineRx‘s AGI-134 induced complete tumor regression in more than half the animals and significantly increased their survival, a preclinical study showed. The ... Read more

January 30, 2018January 30, 2018

Treos Bio’s Cancer Vaccine Cleared to Enter Phase 1 Trial for Advanced Colon Cancer

News

A Phase 1 clinical trial sponsored by Treos Bio will soon begin to evaluate the company’s PolyPEPI 1018 cancer vaccine for the treatment of metastatic colorectal cancer (mCRC). The start of the trial ... Read more

January 29, 2018

OBI Pharma to Begin Phase 1 Trial of OBI-888 in Advanced Solid Tumor Patients

News

OBI Pharma will soon initiate a Phase 1 trial of its OBI-888, an immunotherapy candidate to treat locally advanced or metastatic solid tumors. The Taiwan biopharma’s announcement comes on the heels of ... Read more

January 26, 2018

Feldan Therapeutics and Green Cross LabCell Collaborate on Natural Killer Cell-based Immunotherapies

News

Green Cross LabCell (GCLC) and Feldan Therapeutics have announced a joint research collaboration to develop a high-performance, natural killer (NK) anticancer treatment with low immunogenicity, meaning it does not trigger ... Read more